anti-HLA-G/CD3 bispecific antibody RO7515629

{
  "id": "MLC-T-ONC-010797",
  "term": "anti-HLA-G/CD3 bispecific antibody RO7515629",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific antibody targeting the tumor-associated antigen (TAA) histocompatibility antigen, class I, G (human leukocyte antigen G; HLA-G) and the CD3 antigen found on T lymphocytes, with potential immune checkpoint inhibiting, immunomodulating and antineoplastic activities. Upon administration, the anti-HLA-G/CD3 bispecific antibody RO7515629 targets and binds to both CD3 on cytotoxic T lymphocytes (CTLs) and HLA-G found on HLA-G-expressing tumor cells. This activates and redirects CTLs to HLA-G-expressing tumor cells, which results in the CTL-mediated cell death of HLA-G-expressing tumor cells. HLA-G, an immune checkpoint normally expressed at the maternal-fetal interface, is expressed across multiple tumor cell types and plays a key role in cancer immune evasion. It inhibits the immune responses by binding to its inhibitory receptors on a variety of immune cells, such as natural killer cells (NKs), T and B lymphocytes, and dendritic cells (DCs).",
  "synonyms": [
    "anti-HLA-G T-cell engager RO7515629",
    "CD3-binding T-cell engager RO7515629",
    "HLA-G TCB RO7515629",
    "HLA-G-TCB RG6353",
    "T-cell bispecific antibody RO7515629",
    "TCB RO7515629",
    "TCE RO7515629"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-hla-g-cd3-bispecific-antibody-ro7515629/"
}